Arcutis Biotherapeutics, Inc. 8-K

What Happened
Arcutis Biotherapeutics, Inc. announced on May 6, 2026 that it filed a Form 8-K (Item 2.02) to furnish a press release reporting its financial results for the quarter ended March 31, 2026. The press release is attached to the filing as Exhibit 99.1; the filing also includes the Inline XBRL cover page as Exhibit 104. The report is signed by Chief Financial Officer Latha Vairavan.

Key Details

• Filing date: May 6, 2026 (Form 8-K).
• Period covered: quarter ended March 31, 2026.
• Exhibit 99.1: Press release with the quarter's financial results (furnished with the 8-K).
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL).
• Signed by: Latha Vairavan, Chief Financial Officer.

Why It Matters
This 8-K provides Arcutis's official, company-issued summary of its quarterly earnings and financial condition for investors and the market. The 8-K itself furnishes the press release but does not include the detailed financial statements beyond the attached release—investors should review Exhibit 99.1 (the press release) and subsequent SEC filings (e.g., Form 10-Q) for full financial detail, revenue figures, and management commentary. The filing signals timely disclosure of quarterly results and compliance with reporting requirements.